Promoting integrity in industry-sponsored clinical drug trials: Conflict of interest issues for Canadian health sciences centres

Law and Ethics in Biomedical Research: Regulation, Conflict of Interest and Liability

Volumn , Issue , 2006, Pages 95-131

  Ferris, Lorraine E ^a,b   Naylor, C David ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84966785454     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (127)

1. Claire Turcotte Maatz, ‘University Physician-Researcher Conflicts of Interest: The Inadequacy of Current Controls and Proposed Reform’ (1992) 7 High Tech. L.J. 137.
2. Erica Rose, ‘Conflicts of Interest in Clinical Research: Legal and Ethical Issues: Financial Conflicts of Interest: How Are We Managing?’ (2001) 8 Widener L. Symp. J. 1.
3. Frances H. Miller, ‘Symposium Trust Relationships Part 1 of 2: Trusting Doctors: Tricky Business When It Comes to Clinical Research’ (2001) 81 B.U.L. Rev. 423.
4. Michael J. Malinowski, ‘Conflicts of Interest in Clinical Research: Legal and Ethical Issues: Institutional Conflicts and Responsibilities in an Age of Academic-Industry Alliances’ (2001) 8 Widener L. Symp. J. 47.
5. Annetine C. Gelijns and Samuel O. Thier, ‘Medical Innovation and Institutional Interdependence: Rethinking University-Industry Connections’ (2002) 287 J. Am. Med. Assoc. 72.
6. Thomas W. Merrill, ‘Symposium: Beyond the Independent Counsel: Evaluating the Options’ (1999) 43 Saint Louis U.L.J. 1047.
7. Dennis F. Thompson, ‘Understanding Financial Conflicts of Interest’ (1993) 329 New Eng. J. Med. 573.
8. Patricia C. Kuszler, ‘Curing Conflicts of Interest in Clinical Research: Impossible Dreams and Harsh Realities’ (2001) 8 Widener L. Symp. J. 115
9. Jerome P. Kassirer and Marcia Angell, ‘Financial Conflicts of Interest in Biomedical Research’ (1993) 329 New Eng. J. Med. 570.
10. Marvin A. Konstam et al., ‘A Device Is Not a Drug’ (2003) 9 J. Cardiac Failure 155.
11. David Blumenthal, ‘Biotech in Northeast Ohio Conference: Conflict of Interest in Biomedical Research’ (2002) 12 Health Matrix 377.
12. Stephen E. Ronai, ‘Growing Public Scrutiny of FDA Clinical Trials: Ethical and Regulatory Compliance to Avoid "Uninformed Consent" and Financial Conflicts of Interest’ (2001) 65 Conn. Med. 661.
13. U.S., House Committee on Government Operations, Are Scientific Misconduct and Conflicts of Interest Hazardous to Our Health? (H.R. Doc. № 688) (Washington, DC: United States Government Printing Office, 1990) at 25
14. Jeanne Lenzer, ‘Alteplase for Stroke: Money and Optimistic Claims Buttress the "Brain Attack" Campaign’ (2002) 324 Brit. Med. J. 723.
15. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, ‘Tissue Plasminogen Activator for Acute Ischemic Stroke’ (1995) 333 New Eng. J. Med. 1581.
16. Alvin Weinberg, ‘Science and Its Limits: The Regulator’s Dilemma,’ in Chris Whipple, ed., De Minimis Risk (New York: Plenum Press, 1987), 27 at 37-8
17. Task Force on Academic Health Centres, From Bench to Bedside: Preserving the Research Mission of Academic Health Centres: Findings and Recommendations of The Commonwealth Fund Task Force on Academic Health Centers (New York: Commonwealth Fund, 1999).
18. Lawrence O. Gostin and Michael O. Witt, ‘Conflict of Interest Dilemmas in Biomedical Research’ (1994) 271 J. Am. Med. Assoc. 547.
19. Industry Canada, Canadian Industry Statistics: Data Tables, Pharmaceutical and Medicine Manufacturing [North American Industry Classification System (NAICS) Code Number 32541], http://www.strategis.ic.gc.ca/canadian_industry_statistics/cis.ns f/IDE/cis32541defe.html.
20. Patented Medicine Prices Review Board, Annual Report (Ottawa: Patented Medicine Prices Review Board, 2002), http://www.pmprb.com/CMFiles/ar2002e21LEF-6252003-6142.pdf.
21. Industry Canada, Canada’s Biopharmaceutical Industry: Open for Global Business, http://www/strategis.ic.gc.ca/SSG/ph01473e.html.
22. Government of Canada, Clinical Trials in Canada: Quality with Cost Advantage. A Canada-United States Comparison (Ottawa: Industry Canada, 2003).
23. http://www.hc-sc.gc.ca/hpfb-dgpsa/ocapi-bpcp/shared_responsibilities_tc_e.html.
24. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, ‘Good Clinical Practice: Consolidated Guideline,’ http://www.ncehr-cnerh.org/english/gcp/.
25. ‘Extent to which a specific intervention, procedure, regimen or service provides a beneficial result under ideal conditions.’ John M. Last, A Dictionary of Epidemiology, 3rd ed. (Oxford: Oxford University Press, 1995)
26. Lorraine E. Ferris, ‘Industry-Sponsored Pharmaceutical Trials and Research Ethics Boards: Are They Cloaked in Too Much Secrecy?’ (2002) 166 Can. Med. Assoc. J. 1279.
27. Michael McDonald, ed., The Governance of Health Research Involving Human Subjects (Ottawa: Law Commission of Canada, 2000).
28. Bernard M. Dickens, ‘Governance Relations in Biomedical Research,’ in McDonald, ed., The Governance of Health Research Involving Human Subjects, § C-1.
29. The Interagency Advisory Panel on Research Ethics (PRE), Process and Principles for Developing a Canadian Governance System for the Ethical Conduct of Research Involving Humans (April 2002), http://www.pre.ethics.gc.ca/english/policyinitiatives/governance01.cfm.
30. National Council on Ethics in Human Research, The Final Report of the Task Force on Accreditation (March 2002), http://www.ncehr-cnerh.org/downloads/FIN_TaskForceReport_EN.pdf.
31. Social Sciences and Humanities Research Council, Standing Committee on Ethics and Integrity, Public Assurance System for Research Involving Humans in Council-Funded Institutions (August 2001), http://www.sshrc.ca/web/about/policies/PAS_e.pdf.
32. Science Advisory Board, Health Canada, ‘A Canadian System of Oversight for the Governance of Research Involving Human Subjects’ (February 2002), http://www.hc-sc.gc.ca/sab-ccs/feb2002_governance _subject_e.pdf.
33. http://222.fda.gov/oc/guidance/financialdis.html.
34. www.library.utoronto.ca/medicine/medUT/hcletter.pdf.
35. http://www.hc-sc.gc.ca/hpfb-dgpsa/inspectorate/food_drug_reg_amend_1024_gcp _e.pdf.
36. Health Products and Food Branch Inspectorate, Summary Report of the Inspections of Clinical Trials Conducted under Voluntary Phase (July 2003), http://www.hc-sc.gc.ca/hpfb-dgpsa/inspectorate/gcp_inspection _sum_rep_entire_e.html.
37. Jeffrey C. Lozon and Robert M. Fox, ‘Academic Health Sciences Centres Laid Bare’ (2002) 2: 3 Healthcare Papers 10.
38. Richard Culbertson, ‘A U.S. Perspective: A Future of Increased Diversification’ (2002) 2: 3 Healthcare Papers 66.
39. Lozon and Fox, ‘Academic Health Sciences Centres Laid Bare.'
40. Michael A. Weber, ‘Impact on the Pharmaceutical Industry of Changes in the American Health Care System: A Physician’s Perspective’ (1994) 24 Seton Hall L. Rev. 1290.
41. Patricia C. Kuszler, ‘Financial Clinical Research and Experimental Therapies: Payment Due, But From Whom?’ (2000) 3 DePaul J. Health Care L. 441.
42. Bryan J. Weiner et al., ‘Organizational Models for Medical School-Clinical Enterprise Relationships’ (2001) 76 Acad. Med. 113.
43. Jay K. Levine, ‘Considering Alternative Organizational Structures for Academic Medical Centers’ (2002) 14: 2 Acad. Clinical Practice 2.
44. ‘Redbook.’ 1940 Statement of Principles on Academic Freedom and Tenure with 1970 Interpretive Comments, http:///www.aaup.org/statements/Redbook/1940stat.htm.
45. C. David Naylor, ‘The CMA’s First Code of Ethics: Medical Morality or Borrowed Ideology?’ (1983) 17: 4 J. Can. Stud. 20.
46. Dickason v. University of Alberta, [1992], 2 S.C.R. 1103.
47. Students for Life v. Alma Mater Society of the University of British Columbia (2003), 15 B.C.L.R. (4th) 358 (S.C.).
48. Canadian Association of University Teachers, Policy Statement on Academic Freedom (May 2003), http://www.caut.ca/English/about/policy/academic freedom.asp.
49. Rebecca S. Eisenberg, ‘Symposium on Academic Freedom: Academic Freedom and Academic Values in Sponsored Research’ (1988) 66 Tex. L. Rev. 1363.
50. David G. Nathan and David J. Weatherall, ‘Academic Freedom in Clinical Research’ (2002) 347 New Eng. J. Med. 1368.
51. Jeffrey M. Drazen, ‘Institutions, Contracts, and Academic Freedom’ (2002) 347 New Eng. J. Med. 1362.
52. Lorraine E. Ferris, Peter A. Singer, and C. David Naylor, ‘Better Governance in Academic Health Sciences Centres: Moving Beyond the Olivieri/Apotex Affair in Toronto’ (2004) 30 J. Med. Ethics 25.
53. Richard A. Deyo et al., ‘The Messenger under Attack: Intimidation of Researchers by Special-Interest Groups’ (1997) 336 New Eng. J. Med. 1176.
54. Association of American Universities, Task Force on Research Accountability, Report on Individual and Institutional Financial Conflict of Interest (October 2001), http://www.aau.edu/research/COI.01.pdf.
55. Brenda L. Beagan, ‘Ethics Review for Human Subjects Research: Interviews with Members of Research Ethics Boards and National Organizations,’ in McDonald, ed., The Governance of Health Research Involving Human Subjects, § E-1.
56. Government of Canada, Clinical Trials in Canada.
57. Frank Davidoff et al., ‘Sponsorship, Authorship and Accountability’ (2001) 135 Annals Internal Med. 463.
58. Thomas Bodenheimer, ‘Uneasy Alliance: Clinical Investigators and the Pharmaceutical Industry’ (2000) 342 New Eng. J. Med. 1539.
59. Kenneth A. Getz, AMCs Rekindling Clinical Research Partnerships with Industry (Boston: Centerwatch, 1999).
60. Stephen Zisson, ‘Losing Ground in the Battle against Development Delays’ (1998) 5: 12 CenterWatch 1 at 1, 3.
61. CenterWatch, ‘Pace of CRO Acquisitions Accelerates’ (2002) 9: 7 Center-Watch 1.
62. Covance Inc. et al., Letter to the Editor, ‘Sponsorship, Authorship, and Accountability’ (2000) 136 Annals Internal Med. 251.
63. Karine Morin et al., ‘Managing Conflicts of Interest in the Conduct of Clinical Trials’ (2002) 287 J. Am. Med. Assoc. 78.
64. Trudo Lemmens and Benjamin Freedman, ‘Ethics Review for Sale?’ (2000) 78 Milbank Q. 547.
65. Jonathan Quick, ‘Maintaining the Integrity of the Clinical Evidence Base’ (2001) 79 Bulletin of the World Health Organization 1093, 76.
66. Marcia Angell, ‘Is Academic Medicine for Sale?’ (2000) 342 New Eng. J. Med. 1516.
67. Martin B. Van Der Weyden, ‘Confronting Conflict of Interest in Research Organisations: Time for National Action’ (2001) 175 Med. J. Aus. 396.
68. Catherine D. DeAngelis, ‘Conflict of Interest and the Public Trust’ (2001) 284 J. Am. Med. Assoc. 2237.
69. John F. Staropoli, ‘Funding and Practice of Biomedical Research’ (2003) 290 J. Am. Med. Assoc. 112.
70. David Korn, ‘Conflicts of Interest in Biomedical Research’ (2000) 284 J. Am. Med. Assoc. 2234.
71. Niteesh K. Choudhry, Henry Thomas Stelfox, and Allan S. Detsky, ‘Relationships between Authors of Clinical Practice Guidelines and the Pharmaceutical Industry’ (2002) 287 J. Am. Med. Assoc. 612.
72. Charles Warlow, ‘Who Pays the Guideline Writers?’ (2002) 324 Brit. Med. J. 726.
73. Lisa A. Bero and Drummond Rennie, ‘Influences on the Quality of Published Drug Studies’ (1996) 12 Int’l J. Tech. Assessment Health Care 209.
74. Patricia Baird, ‘Getting It Right: Industry Sponsorship and Medical Research’ (2003) 168 Can. Med. Assoc. J. 1267.
75. Gelijns and Thier, ‘Medical Innovation and Institutional Interdependence’.
76. Paul S. Thomas, Ken-Soon Tan, and Deborah H. Yates, ‘Sponsorship, Authorship, and Accountability’ Letter (2002) 359 Lancet 351.
77. Henry Thomas Stelfox et al., ‘Conflict of Interest in the Debate over Calcium-Channel Antagonists’ (1998) 338 New Eng. J. Med. 101.
78. Mark Friedberg et al., ‘Evaluation of Conflict of Interest in Economic Analyses of New Drugs Used in Oncology’ (1999) 282 J. Am. Med. Assoc. 1453.
79. Bruce M. Psaty and Drummond Rennie, ‘Stopping Medical Research to Save Money: A Broken Pact with Researchers and Patients’ (2003) 289 J. Am. Med. Assoc. 2128.
80. Kenneth Boyd, ‘Early Discontinuation Violates Helsinki Principles’ (2001) 322 Brit. Med. J. 605.
81. Michel Lièvre et al., ‘Premature Discontinuation of Clinical Trial for Reasons Not Related to Efficacy, Safety, or Feasibility’ (2001) 322 Brit. Med. J. 603.
82. ‘Premature Termination of Clinical Trials’ (2003) 290 J. Am. Med. Assoc. 595, 80
83. David Blumenthal et al., ‘Withholding Research Results in Aca demic Life Science: Evidence from a National Survey of Faculty’ (1997) 277 J. Am. Med. Assoc. 1224.
84. Iain Chalmers, ‘Underreporting Research Is Scientific Misconduct’ (1990) 263 J. Am. Med. Assoc. 1405.
85. Drummond Rennie, ‘Thyroid Storm’ (1997) 277 J. Am. Med. Assoc. 1238.
86. Bodenheimer, ‘Uneasy Alliance’.
87. Robert A. Phillips and John Hoey, ‘Constraints of Interest: Lessons at the Hospital for Sick Children’ (1998) 159 Can. Med. Assoc. J. 955.
88. Jerome M. Stern and R. John Simes, ‘Publication Bias: Evidence of Delayed Publication in a Cohort Study of Clinical Research Projects’ (1997) 315 Brit. Med. J. 640.
89. Bero and Rennie, ‘Influences on the Quality of Published Drug Studies’.
90. Joel Lexchin et al., ‘Pharmaceutical Industry Sponsorship and Research Outcome and Quality: Systematic Review’ (2003) 326 Brit. Med. J. 326.
91. Paula A. Rochon et al., ‘A Study of Manufacturer-Supported Trials of Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Arthritis’ (1994) 154 Arch. Internal Med. 157.
92. Justin E. Bekelman, Yan Li, and Cary P. Gross, ‘Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review’ (2003) 289 J. Am. Med. Assoc. 454.
93. Philippa J. Easterbrook et al., ‘Publication Bias in Clinical Research’ (1991) 337 Lancet 867.
94. Kay Dickersin, Simon Chan, and Thomas C. Chalmers, ‘Publication Bias and Clinical Trials’ (1987) 8 Controlled Clinical Trials 343.
95. Richard A. Davidson, ‘Source of Funding and Outcome of Clinical Trials’ (1986) 1 J. Gen. Internal Med. 155.
96. Mildred K. Cho and Lisa A. Bero, ‘The Quality of Drug Studies Published in Symposium Proceedings’ (1996) 124 Annals Internal Med. 485.
97. Richard Smith, ‘Medical Journals and Pharmaceutical Companies: Uneasy Bedfellows’ (2003) 326 Brit. Med. J. 1202.
98. Drummond Rennie, ‘Fair Conduct and Fair Reporting of Clinical Trials’ (1999) 282 J. Am. Med. Assoc. 1766, 82
99. Arnold S. Relman, ‘Dealing with Conflicts of Interest’ (1984) 310 New Eng. J. Med. 1182.
100. Marcia Angell, Robert D. Utiger, and Alastair J.J. Wood, ‘Disclosure of Authors’ Conflicts of Interest: A Follow-Up’ (2002) 342 New Eng. J. Med. 586.
101. Drummond Rennie, Annette Flanagin, and Richard M. Glass, ‘Conflicts of Interest in the Publication of Science’ (1991) 266 J. Am. Med. Assoc. 266.
102. Richard Smith, ‘Conflict of Interest and the BMJ’ (1994) 308 Brit. Med. J. 4.
103. S. Van McCrary et al., ‘A National Survey of Policies on Disclosure of Conflicts of Interest in Biomedical Research’ (2000) 343 New Eng. J. Med. 1621.
104. Sheldon Krimsky and Leslie S. Rothenberg, ‘Conflict of Interest Policies and Science and Medical Journals: Editorial Practices and Author Disclosures’ (2001) 7 Sci. Engineering Ethics 205.
105. Fran Van Kolfschooten, ‘Conflicts of Interest: Can You Believe What You Read?’ (2002) 416 Nature 360.
106. International Committee of Medical Journal Editors, Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication (November 2003), http://www.icmje.org.
107. Elizabeth Wager, ‘How to Dance with Porcupines: Rules and Guidelines on Doctors’ Relations with Drug Companies’ (2003) 326 Brit. Med. J. 1196.
108. Stanley G. Korenman, ‘The Role of Journal Editors in the Responsible Conduct of Industry-Sponsored Biomedical Research and Publication: A View from the Other Side of the Editor’s Desk’ (2003) 26 Science Editor 42.
109. Hiram C. Polk, Jr et al., ‘Consensus Statement on Scientific Data from Clinical Trials and Investigators’ Responsibilities and Rights’ (2002) 183 Am. J. Surgery 605.
110. Richard Smith, ‘Maintaining the Integrity of the Scientific Record’ (2001) 323 Brit. Med. J. 588.
111. Lawrence J. Hirsch, ‘Conflicts of Interest in Drug Development: The Practices of Merck & Co., Inc.’ (2002) 8 Sci. Engineering Ethics 429.
112. Pharmaceutical Research and Manufacturers of America, Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results (July 2002), http:// www.phrma.org/publications/policy/2002-07-18.490.pdf.
113. Elizabeth Wager, Elizabeth A. Field, and Leni Grossman, ‘Good Publication Practice for Pharmaceutical Companies’ (2003) 19 Curr. Med. Research Opinion 149
114. Debashis Singh, ‘Drug Companies Advised to Publish Unfavourable Trial Results’ (2003) 326 Brit. Med. J. 1163
115. Kevin A. Schulman et al., ‘A National Survey of Provisions in Clinical-Trial Agreements between Medical Schools and Industry Sponsors’ (2002) 347 New Eng. J. Med. 1335.
116. C. David Naylor, ‘Early Toronto Experience with New Standards for Industry-Sponsored Clinical Research: A Progress Report’ (2002) 166 Can. Med. Assoc. J. 453.
117. Association of American Medical Colleges, Task Force on Financial Conflicts of Interest in Clinical Research, Protecting Subjects, Preserving Trust, Promoting Progress II: Principles and Recommendations for Oversight of an Institution’s Financial Interests in Human Subjects Research (October 2002), http://www.aamc.org/members/coitf/2002coireport.pdf.
118. Association of American Medical Colleges, Task Force on Financial Conflicts of Interest in Clinical Research, Protecting Subjects, Preserving Trust, Promoting Progress - Policy and Guidelines for the Oversight of Individual Financial Interest in Human Subjects Research (December 2001), www.aamc.org/members/coitf/firstreport.pdf.
119. American Association of University Professors, Committee on Academic Freedom and Tenure, Statement on Corporate Funding of Academic Research (May 2001), http://www.aaup.org/statements/Redbook/repcorf.htm.
120. Bernardine Healy et al., ‘Conflict of Interest Guidelines for a Multicenter Clinical Trial of Treatment after Coronary-Artery Bypass-Graft Surgery’ (1989) 320 New Eng. J. Med. 949.
121. Eric J. Topol et al., ‘Confronting the Issues of Patient Safety and Investigator Conflict of Interest in an International Clinical Trial of Myocardial Reperfusion’ (1992) 19 J. Am. College Cardiology 1123.
122. Peter J. Harrington, ‘Faculty Conflicts of Interest in an Age of Academic Entrepreneurialism: An Analysis of the Problem, the Law and Selected University Policies’ (2001) 27 J.C. & U.L. 774.
123. Bernard Lo, Leslie E. Wolf, and Abiona Berkeley, ‘Conflict of Interest Policies for Investigators in Clinical Trials’ (2000) 343 New Eng. J. Med. 1616.
124. Van McCrary et al., ‘National Survey of Policies on Disclosure of Conflicts of Interest’.
125. Mildred K. Cho et al., ‘Policies on Faculty Conflicts of Interest at U.S. Universities’ (2000) 284 J. Am. Med. Assoc. 2203.
126. Dennis F. Thompson, ‘Understanding Financial Conflicts of Interest’ (1993) 329 New England J. Med. 573.
127. Medical Research Council of Canada, Natural Sciences and Engineering Research Council of Canada, and the Social Sciences and Humanities Research Council of Canada, Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (Ottawa: Public Works and Government Services Canada, 1998), http://www.pre.ethics.gc.ca/english/policystatement/policystateme nt.cfm.